| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/30/2004 | EP1432409A1 Granulate or powder for producing coating or binding agents for medicaments |
| 06/30/2004 | EP1432408A1 Pharmaceutical compositions comprising colloidal silicon dioxide |
| 06/30/2004 | EP1432407A1 Lisinopril compositions having large-particle dcpd |
| 06/30/2004 | EP1432406A2 Pharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support |
| 06/30/2004 | EP1432405A1 Ibuprofen salt emulsifiers and cream formulations containing same |
| 06/30/2004 | EP1432404A1 Edible composition and dosage form comprising an edible shell |
| 06/30/2004 | EP1432403A2 Liposome loading with metal ions |
| 06/30/2004 | EP1263325A4 Embolic agents visible under ultrasound |
| 06/30/2004 | EP1244418B1 Oil-in-water type cosmetic or dermatological preparations |
| 06/30/2004 | EP1237543A4 Effervescent histamine h2 antagonist composition |
| 06/30/2004 | EP1227817B1 Ciclesonide-containing aqueous pharmaceutical composition |
| 06/30/2004 | EP1206281B1 Formulation containing moxifloxacin and sodium chloride |
| 06/30/2004 | EP1173453B1 Crystallization of glucopyranosylalditols, crystalline glucopyranosylalditol product and use thereof |
| 06/30/2004 | EP1169063B1 Treatment of intracellular infection |
| 06/30/2004 | EP1069889B1 Partikulärer wirkstoffträger für die pulmonale applikation |
| 06/30/2004 | EP0977600B1 Contrast agents targetting receptors associated with angiogenesis |
| 06/30/2004 | EP0915902A4 Transgenic animals expressing artificial epitope-tagged proteins |
| 06/30/2004 | EP0724643B1 Endosomolytically active particles |
| 06/30/2004 | EP0690722B1 Composition and method for reducing toxicity of biologically-active factors |
| 06/30/2004 | CN1509188A Immunoconjugates made of egg-yolk antibiodies (IGY), production and use thereof in diagnoses and therapy |
| 06/30/2004 | CN1509187A Cytotoxic CD44 antibody immunoconjugates |
| 06/30/2004 | CN1509186A Composition containing epigallocatechin gallate |
| 06/30/2004 | CN1509185A Medicinal composition |
| 06/30/2004 | CN1509172A Pirenzepine ophthalmic gel |
| 06/30/2004 | CN1509167A Process for producing stable enteric sugar-coated tablet |
| 06/30/2004 | CN1509166A Liposome composition for improved intracellular delivery of therapeutic agent |
| 06/30/2004 | CN1509165A Liquid pharmaceutical composition |
| 06/30/2004 | CN1509164A System for delivering consmetics and pharmaceuticals. |
| 06/30/2004 | CN1509162A Cosmetics |
| 06/30/2004 | CN1509144A Prebiotic and probiotic compositions and method for use in gut-based therapies |
| 06/30/2004 | CN1507918A Transdermal promotor glycerin triacetate |
| 06/30/2004 | CN1155648C Silicone gel containing salicylic acid |
| 06/30/2004 | CN1155620C Thioether conjugates |
| 06/30/2004 | CN1155618C PEG-interferon conjugates |
| 06/30/2004 | CN1155408C Stable lyophilized pharmaceutical substance from monoclonal or polyclonal antibodies |
| 06/30/2004 | CN1155404C Method of preveting TPO adsorption and stable TPO-contg. composition |
| 06/30/2004 | CN1155388C Orally administrable solid ribavirin dosafe forms and process for making them |
| 06/30/2004 | CN1155385C Formulation comprising testosteron undecanoate and castor oil |
| 06/30/2004 | CN1155379C Use of Yiliqutan in preparing medicine for preventing recurrence of cephalagra |
| 06/30/2004 | CN1155373C S-(3-hydroxypropyl)-L-cysteine composition as oral medicine |
| 06/30/2004 | CN1155372C Electrically assisted delivery conveyor and using method thereof |
| 06/30/2004 | CN1155370C Process for preparing medicinal granule |
| 06/30/2004 | CN1155369C Modified release oral pharmaceutical composition contg. 5-ASA and method for treatment of bowel diseases |
| 06/30/2004 | CN1155367C Micropartical inhalation formulations |
| 06/30/2004 | CA2454629A1 Amino acids in micelle preparation |
| 06/30/2004 | CA2414148A1 Targeted ligands |
| 06/29/2004 | US6756481 IL-23 receptor binding compositions |
| 06/29/2004 | US6756480 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 06/29/2004 | US6756472 Process for producing polymer |
| 06/29/2004 | US6756397 Such as (s)-n-(2-((1-chloromethyl)-1,2-dihydro-5-((4-methylpiperazino)carbonyloxy) -3h-benz(e) indol-3-yl)carbonyl)-1h-indol-5-yl)-5-((3-methyldithio-1-oxopropyl)-amino) -1h-indole-2-carboxamide; enhanced water solubility and stability |
| 06/29/2004 | US6756363 Solutions and films of glycated chitosan |
| 06/29/2004 | US6756362 Anionic polymers including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin, dextran sulfate, pentosan polysulfate, hyaluronic acid and alginate. |
| 06/29/2004 | US6756354 Stabilization of drugs |
| 06/29/2004 | US6756062 Preparation of drug particles using evaporation precipitation into aqueous solutions |
| 06/29/2004 | US6756059 Prepared by melt processing a hydrophobic polymer composition that includes repeating pyrrolidone/alkylene groups containing at least 10 carbon atoms, and a hydrophilic polymer composition including repeating carboxylic or hydroxyl groups |
| 06/29/2004 | US6756055 Administering to a mammal formulation of cationic lipids and a substance that affects angiogenesis; allowing formulation to associate with angiogenic endothelial cells of an angiogenic blood vesselsuch that it enters cells |
| 06/29/2004 | US6756052 Effects localized increase in temperature and/or blood flow using rubefacient agent |
| 06/29/2004 | US6756051 Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same |
| 06/29/2004 | US6756050 Containing yeast cells cultured in presence of alternating electric field |
| 06/29/2004 | US6756047 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 06/29/2004 | US6756044 Heightening response of immune effector cells |
| 06/29/2004 | US6756041 Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process |
| 06/29/2004 | US6756037 Polymer transport system for active biological compounds |
| 06/29/2004 | US6756036 Methods for treating cancer using PSCA antibodies and fragments thereof |
| 06/29/2004 | CA2366304C Novel method of treatment |
| 06/29/2004 | CA2311391C Skin protection composition |
| 06/29/2004 | CA2296726C Combination therapy |
| 06/29/2004 | CA2293815C Film-coated tablet for improved upper gastrointestinal tract safety |
| 06/29/2004 | CA2275392C New aqueous medicament preparations for the production of propellent gas-free aerosols |
| 06/29/2004 | CA2234936C Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine |
| 06/29/2004 | CA2204451C Method of selecting a salt for making an inclusion complex |
| 06/29/2004 | CA2146645C Plaster for the transdermal administration of volatile, pharmaceutically active, chemically alkaline ingredients and processes for producing the same |
| 06/29/2004 | CA2135192C Vaccinal fluid water-in-oil emulsions containing a metabolizable oil |
| 06/29/2004 | CA2131285C Pharmaceutical inhalation compositions |
| 06/29/2004 | CA2031518C Endothelial cell-leukocyte adhesion molecules (elams) and molecules involved in leukocyte adhesion (milas) |
| 06/27/2004 | CA2454050A1 Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
| 06/24/2004 | WO2004053192A1 Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity |
| 06/24/2004 | WO2004053054A2 Nk cell receptor conjugates for treating malignancies |
| 06/24/2004 | WO2004052931A1 Negatively charged antiviral protein conjugates |
| 06/24/2004 | WO2004052907A1 Nucleic acid labeling compounds |
| 06/24/2004 | WO2004052406A1 Coupling of dicarboxylic compounds by convertion into anhdrids |
| 06/24/2004 | WO2004052405A1 Oral formulations for poorly absorptive hydrophilic drugs |
| 06/24/2004 | WO2004052403A1 Preservative for ophthalmology |
| 06/24/2004 | WO2004052402A1 Hypercoiling polymers and their use in cellular delivery |
| 06/24/2004 | WO2004052401A2 Compositions and methods of delivery of pharmacological agents |
| 06/24/2004 | WO2004052400A1 Pharmaceutical formulation and a method of making same |
| 06/24/2004 | WO2004052358A1 Urushiol induced contact dermatitis treatment and method of use |
| 06/24/2004 | WO2004052354A1 Propofol-containing fat emulsions |
| 06/24/2004 | WO2004052347A1 Transmucosal and transdermal medicaments with an improved active ingredient absorption |
| 06/24/2004 | WO2004052336A2 High viscosity liquid controlled delivery system and medical or surgical device |
| 06/24/2004 | WO2004052333A1 Pharmaceutical compositions for the pulmonary delivery of aztreonam |
| 06/24/2004 | WO2004052287A2 Topical composition for heightened sensitivity |
| 06/24/2004 | WO2004035629A3 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 06/24/2004 | WO2004021993A3 Modified asialo-interferons and uses thereof |
| 06/24/2004 | WO2004017903A3 Methods for treating fungal infections |
| 06/24/2004 | WO2004014304A3 Electrospun amorphous pharmaceutical compositions |
| 06/24/2004 | WO2004014156B1 A chemical carrier based on a beta-limit dextrin |
| 06/24/2004 | WO2004009665A3 Dendrimers as molecular translocators |
| 06/24/2004 | WO2004008101A3 The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 06/24/2004 | WO2003105724A3 Novel maxi-k channel blockers, methods of use and process for making the same |